Incyte Corp. (INCY)
105.39
+2.16
(+2.09%)
USD |
NASDAQ |
Jun 10, 16:00
105.90
+0.51
(+0.48%)
Pre-Market: 08:11
Incyte EPS Diluted (Quarterly) : 1.467 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.467 |
| December 31, 2025 | 1.462 |
| September 30, 2025 | 2.106 |
| June 30, 2025 | 2.038 |
| March 31, 2025 | 0.7982 |
| December 31, 2024 | 1.019 |
| September 30, 2024 | 0.5436 |
| June 30, 2024 | -2.038 |
| March 31, 2024 | 0.7462 |
| December 31, 2023 | 0.8892 |
| September 30, 2023 | 0.7573 |
| June 30, 2023 | 0.9021 |
| March 31, 2023 | 0.0962 |
| December 31, 2022 | 0.1266 |
| September 30, 2022 | 0.5031 |
| June 30, 2022 | 0.7218 |
| March 31, 2022 | 0.1704 |
| December 31, 2021 | 2.54 |
| September 30, 2021 | 0.8177 |
| June 30, 2021 | 0.6725 |
| March 31, 2021 | 0.2413 |
| December 31, 2020 | 0.6774 |
| September 30, 2020 | -0.0695 |
| June 30, 2020 | 1.317 |
| March 31, 2020 | -3.325 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.5079 |
| September 30, 2019 | 0.589 |
| June 30, 2019 | 0.4843 |
| March 31, 2019 | 0.47 |
| December 31, 2018 | 0.32 |
| September 30, 2018 | 0.14 |
| June 30, 2018 | 0.24 |
| March 31, 2018 | -0.19 |
| December 31, 2017 | -0.7087 |
| September 30, 2017 | 0.17 |
| June 30, 2017 | -0.06 |
| March 31, 2017 | -0.96 |
| December 31, 2016 | 0.05 |
| September 30, 2016 | 0.19 |
| June 30, 2016 | 0.18 |
| March 31, 2016 | 0.12 |
| December 31, 2015 | 0.29 |
| September 30, 2015 | -0.22 |
| June 30, 2015 | 0.05 |
| March 31, 2015 | -0.11 |
| December 31, 2014 | -0.22 |
| September 30, 2014 | 0.33 |
| June 30, 2014 | -0.22 |
| March 31, 2014 | -0.21 |
| December 31, 2013 | -0.26 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.508 |
| BioMarin Pharmaceutical, Inc. | 0.5431 |
| Vertex Pharmaceuticals, Inc. | 4.024 |
| Mirum Pharmaceuticals, Inc. | -13.43 |
| Biogen, Inc. | 2.153 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 303.33M |
| Revenue (Quarterly) | 1.273B |
| Total Expenses (Quarterly) | 969.35M |
| Enterprise Value | 17.10B |
| Gross Profit Margin (Quarterly) | 90.46% |
| Profit Margin (Quarterly) | 23.83% |
| Earnings Yield | 6.71% |
| Operating Earnings Yield | 6.78% |
| Normalized Earnings Yield | 6.131 |